The board of directors of Ocumension Therapeutics announced that (i) due to personal reasons, Ms. Yun JI ("Ms. JI") has tendered her resignation as a joint company secretary of the Company (the "Joint Company Secretary"), and will cease to act as a Joint Company Secretary with effect from September 30, 2023; and (ii) Ms. CHAU Hing Ling ("Ms. CHAU") has tendered her resignation as (a) a Joint Company Secretary, and (b) an authorized representative of the Company pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (the "Authorized Representative"), and will cease to act as a Joint Company Secretary and an Authorized Representative with effect from September 30, 2023. Following the cessation of Ms. JI and Ms. CHAU to act as a Joint Company Secretary, respectively, the Board announced that (i) Mr. Tim RUAN and Ms. Tingchan CHEN have been appointed as Joint Company Secretaries in place of Ms. JI and Ms. CHAU with effect from September 30, 2023; and (ii) Mr. RUAN has been appointed as an Authorized Representative in place of Ms. CHAU with effect from September 30, 2023. The biographical details of Mr. RUAN and Ms. CHEN are set out below: MR. RUAN Mr. RUAN, aged 37, has been chief financial officer since January 12, 2023, responsible for financial management and investor relations of the Group.

Mr. RUAN has extensive experience of financial management. Prior to joining Group, he served as an executive director of the investment banking division of Goldman Sachs (Asia) L.L.C. from November 2020 to January 2023, primarily responsible for affairs in debt and equity capital markets and M&A. From January 2018 to November 2020, he served as a vice president of the investment banking division of Morgan Stanley Asia Limited. From February 2016 to January 2018, he acted as an associate within the investment banking division of Nomura International (Hong Kong) Limited.

From September 2013 to January 2016, he served as associate at Sullivan & Cromwell LLP. Mr. RUAN graduated from The Hong Kong University of Science and Technology in November 2021 with a master's degree of science, majoring in biotechnology. He graduated from The University of New South Wales in December 2009 with bachelor's degree of laws and bachelor's degree of commerce majoring in finance.

MS. CHEN Ms. CHEN, aged 29, joined the Company on July 1, 2021 and currently serves as the securities affairs manager of the Company. Ms. CHEN has several years of experience in corporate governance and company secretarial practice. Prior to joining Group, Ms. CHEN served as the senior manager of capital markets and investor relations at Shanghai Fosun High Technology (Group) Co.

Ltd., a subsidiary of Fosun International Limited from September 2020 to June 2021. From April 2017 to September 2020, she served as the supervisor of the secretariat to the board at Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. Ms. CHEN obtained her bachelor's degree in business administration from The Chinese University of Hong Kong in November 2016 and her master's degree in corporate governance from Hong Kong Metropolitan University in March 2023.

She has been an associate member of The Hong Kong Chartered Governance Institute since July 2023.